George J Brewer1. 1. University of Michigan Medical School, Departments of Human Genetics and Internal Medicine, G061XMBNI, Ann Arbor, MI 48109-5720, USA. brewergj@umich.edu
Abstract
BACKGROUND: Tetrathiomolybdate (TM), an anticopper drug, has been developed for the neurologic presentation of Wilson's disease. In animal models, lowering copper levels with TM produces antifibrotic, anti-inflammatory, antiautoimmune, and anticancer effects, thought to be due to inhibition of many cytokines that are dependent on available copper for their activity. Clinical testing has been done relatively extensively in Wilson's disease and advanced cancers, but remains in its infancy in other diseases. OBJECTIVES: To review current preclinical and clinical studies done with TM, and our current knowledge of TM efficacy and toxicity. METHODS: We have reviewed the last 10 years of literature on TM therapy. RESULTS/ CONCLUSION: TM has excellent efficacy and acceptable toxicity for the initial treatment of neurologically presenting Wilson's disease. TM has excellent efficacy in animal models of fibrotic, inflammatory, autoimmune, and neoplastic diseases, as well as Alzheimer's disease models.
BACKGROUND:Tetrathiomolybdate (TM), an anticopper drug, has been developed for the neurologic presentation of Wilson's disease. In animal models, lowering copper levels with TM produces antifibrotic, anti-inflammatory, antiautoimmune, and anticancer effects, thought to be due to inhibition of many cytokines that are dependent on available copper for their activity. Clinical testing has been done relatively extensively in Wilson's disease and advanced cancers, but remains in its infancy in other diseases. OBJECTIVES: To review current preclinical and clinical studies done with TM, and our current knowledge of TM efficacy and toxicity. METHODS: We have reviewed the last 10 years of literature on TM therapy. RESULTS/ CONCLUSION:TM has excellent efficacy and acceptable toxicity for the initial treatment of neurologically presenting Wilson's disease. TM has excellent efficacy in animal models of fibrotic, inflammatory, autoimmune, and neoplastic diseases, as well as Alzheimer's disease models.
Authors: Haijun Zhang; Di Chen; Jonathan Ringler; Wei Chen; Qiuzhi Cindy Cui; Stephen P Ethier; Q Ping Dou; Guojun Wu Journal: Cancer Res Date: 2010-04-27 Impact factor: 12.701
Authors: Joseph F Quinn; Christopher J Harris; Katherine E Cobb; Christopher Domes; Martina Ralle; George Brewer; Teri L Wadsworth Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi Journal: Mol Oncol Date: 2015-02-21 Impact factor: 6.603